Scientists race to develop vaccine for new coronavirus

Sun, 2020-02-09 05:45

SINGAPORE: Scientists from the United States to Australia are
using new technology in an ambitious, multi-million-dollar drive to
develop a vaccine in record time to tackle China’s coronavirus
The new virus has spread rapidly since emerging late last year in
China, killing more than 800 people in the mainland and infecting
over 37,000. Cases have been reported in two dozen other
Coming up with any vaccine typically takes years, and involves a
lengthy process of testing on animals, clinical trials on humans
and regulatory approvals.
But several teams of experts are racing to develop one quicker,
backed by an international coalition that aims to combat emerging
diseases, and Australian scientists hope theirs could be ready in
six months.
“It is a high-pressure situation and there is a lot of weight on
us,” said senior researcher Keith Chappell, part of the group
from Australia’s University of Queensland.
But the scientist added he took “some solace” knowing several
teams around the world were engaged in the same mission.
“The hope is that one of these will be successful and can contain
this outbreak,” he said.
But even a timeframe of six months looks agonizingly slow with the
virus, believed to have emerged from a market selling wild animals,
killing close to 100 people every day in mainland China.
Efforts are being led by the Coalition for Epidemic Preparedness
Innovations (CEPI), a body established in 2017 to finance costly
biotechnology research in the wake of an Ebola outbreak in West
Africa that killed more than 11,000 people.
With a mission to speed up the development of vaccines, CEPI is
pouring millions of dollars into four projects around the world and
has put out a call for more proposals.
The projects hope to use new technology to develop vaccines that
can be tested in the near future.


This section contains relevant reference points, placed in
(Opinion field)

The body’s CEO, Richard Hatchett, said the aim was to start
clinical testing in just 16 weeks.
German biopharmaceutical company CureVac and US-based Moderna
Therapeutics are developing vaccines based on “messenger RNA”
— instructions that tell the body to produce proteins — while
Inovio, another American firm, is using DNA-based technology.
DNA- and RNA-based vaccines use the genetic coding of the virus to
trick the body’s cells into producing proteins identical to those
on the surface of the pathogen, explained Ooi Eng Eong, deputy
director of the emerging infectious diseases program at the
Duke-NUS Medical School in Singapore.
The immune system learns to recognize the proteins so that it is
ready to find and attack the virus when it enters the body.
The Australian researchers are using “molecular clamp”
technology invented by the university’s scientists that allows
them to rapidly develop new vaccines based solely on a virus DNA
French scientists at the Pasteur Institute are modifying the
measles vaccine to work against the coronavirus, but do not expect
it to be ready for about 20 months.
Meanwhile, the Chinese Center for Disease Control and Prevention
has also started developing vaccines, according to the state-run
Xinhua news agency.
Health authorities weigh the risks and benefits in vaccine
approvals and if there is a public health emergency, the process
could be shortened, said Ooi of the Duke-NUS Medical School.
But he added that “paradoxically, if the situation improves, then
actually the pathway for vaccines would be longer.”
“If there’s a lot of these new coronavirus cases around, then
you accept some risk, because of the tremendous amount of benefit
you can derive, whereas if there are not many cases, the tolerance
for risk would be very low.”
While there is no vaccine for the coronavirus, some doctors are
trying out a potent brew of anti-retroviral and flu drugs to treat
those infected, but the science is inconclusive as to whether they
are effective.
Ultimately, scientists may end up in the same situation they were
during the 2002-2003 outbreak of Severe Acute Respiratory Syndrome
(SARS) — it died out before a vaccine could be fully
A close cousin of the new coronavirus, SARS spread around the world
and killed nearly 800.
But Ong Siew Hwa, the director of Acumen Research Laboratories, a
biotech company in Singapore, said efforts to develop a vaccine for
the new virus should continue even if the outbreak ends.
“I think a vaccine will definitely be important,” she said.
“If it’s not in time for this round, it is important for the
next time.”

Main category: 

Deaths from China’s coronavirus outbreak surpass deaths from
SARSTwo new cases of coronavirus in UAE
Source: *FS – All – Science News Net
Scientists race to develop vaccine for new coronavirus